17 Sep 2012 - 18 Sep 2012 - London, United Kingdom
Since its introduction in 2005 next-generation sequencing (NGS) has fundamentally altered genomics research. Large knowledge-gaining experiments are in progress that were financially unjustifiable or even impossible five years ago. These include metagenomics to compare different disease states or patient variablility, genome sequencing of model and pathogenic species or ELT compound library screening techniques.
NGS is now successfully utilised by biopharmaceutical companies from the earliest stages of drug discovery to provide detailed genomic data and clinical applications are now emerging. These range from investigating the molecular basis of drug resistance and planning antimicrobial regimens, to vaccine development and disease diagnostics. In the rapidly growing field of personalised medicine, eight percent of medicines now have a biomarker or stratified element as compared to just a few percent five years ago.
As sequencing costs continue to fall, the future will see even faster identification of responders and non-responders, benefiting patients, prescribers and payors.
Why should you attend this event? Join us for two days of insights and case studies from leading experts and industry executives, enabling you to:
* Generate longer nucleic acid and oligonucleotide sequences of higher quality
* Increase consensus accuracy and genome coverage
* Maximise the alignment and assembly of NGS reads with reference sequences
* Enhance signal-to-noise measurements in real-time sequencing
* Utilise exomics to elucidate gene families implicated in disease or pharmacogenetic effects
* Improve mapping in repetitive regions when resequencing
* Catalogue the transcriptomes of cells, tissues and pathogens
* Perform quantitative applications more effectively with third generation platforms
* Clarify analysis requirements prior to epigenomic studies